The World Health Organization on Wednesday announced that it is abandoning use of the anti-malaria drug hydroxychloroquine in the Solidarity trial—the organization’s massive, global clinical trial of potential COVID-19 treatments.

The WHO cited early data from the trial and others showing that hydroxychloroquine does not lower the risk of death or provide any other clinical benefit in hospitalized patients.

“Investigators will not randomize further patients to hydroxychloroquine in the Solidarity trial,” the WHO said in a statement. “Patients who have already started hydroxychloroquine but who have not yet finished their course in the trial may complete their course or stop at the discretion of the supervising physician.”